Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5564]

Consolidation treatment delays do not compromise survival in MRD-negative adult...

Prof Bhavana Bhatnagar - WVU Medicine Wheeling Hospital, Wheeling, USA

Consolidation treatment delays do not compromise survival in MRD-negative adult ALL ( Prof Bhavana Bhatnagar - WVU Medicine Wheeling Hospital, Wheeling, USA )

Multimodal AI model augments Oncotype DX in predicting distant recurrence in...

Dr Joseph Sparano - Icahn School of Medicine at Mount Sinai, New York, USA

Multimodal AI model augments Oncotype DX in predicting distant recurrence in HR+/HER2 node negative BC ( Dr Joseph Sparano - Icahn School of Medicine at Mount Sinai, New York, USA )

Higher tumour-infiltrating lymphocytes predict better pathologic response in...

Prof Sunil Badve - Emory University, Atlanta, USA

Higher tumour-infiltrating lymphocytes predict better pathologic response in HER2-positive breast cancer ( Prof Sunil Badve - Emory University, Atlanta, USA )

Dasatinib, prednisone, and blinatumomab combination shows promising outcomes in...

Dr Anjali Advani - Cleveland Clinic, Cleveland, USA

Dasatinib, prednisone, and blinatumomab combination shows promising outcomes in elderly patients with Ph+ ALL ( Dr Anjali Advani - Cleveland Clinic, Cleveland, USA )

Blinatumomab plus chemotherapy shows manageable toxicity in adults with Ph- B...

Dr Anjali Advani - Cleveland Clinic, Cleveland, USA

Blinatumomab plus chemotherapy shows manageable toxicity in adults with Ph- B-ALL ( Dr Anjali Advani - Cleveland Clinic, Cleveland, USA )

Tucatinib added to trastuzumab and pertuzumab improves PFS in first-line HER2...

Dr Erika Hamilton - Sarah Cannon Research Institute, Nashville, USA

Tucatinib added to trastuzumab and pertuzumab improves PFS in first-line HER2-positive metastatic breast cancer ( Dr Erika Hamilton - Sarah Cannon Research Institute, Nashville, USA )

Pirtobrutinib significantly improves PFS in treatment-naïve CLL/SLL compared to...

Prof Wojciech Jurczak - Maria Sklodowska-Curie National Research Institute of...

Pirtobrutinib significantly improves PFS in treatment-naïve CLL/SLL compared to bendamustine plus rituximab ( Prof Wojciech Jurczak - Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland )

Longer follow-up shows promising PFS + MRD negativity for mosunetuzumab use in...

Dr John Burke - Rocky Mountain Cancer Centers, Aurora, USA

Longer follow-up shows promising PFS + MRD negativity for mosunetuzumab use in untreated high tumour burden follicular lymphoma ( Dr John Burke - Rocky Mountain Cancer Centers, Aurora, USA )

Rusfertide provides durable control of haematocrit and phlebotomy reduction in...

Dr Andrew Kuykendall - Moffitt Cancer Center, Tampa, USA

Rusfertide provides durable control of haematocrit and phlebotomy reduction in polycythemia vera ( Dr Andrew Kuykendall - Moffitt Cancer Center, Tampa, USA )

Fixed-duration targeted treatment as effective as TKI Inhibitor therapy for CLL

Dr Othman Al-Sawaf - University Hospital of Cologne, Cologne, Germany

Fixed-duration targeted treatment as effective as TKI Inhibitor therapy for CLL ( Dr Othman Al-Sawaf - University Hospital of Cologne, Cologne, Germany )

MRD validated as a surrogate endpoint for survival in AML

Dr Jesse Tettero - The Hourigan Lab, Washington, D.C., USA

MRD validated as a surrogate endpoint for survival in AML ( Dr Jesse Tettero - The Hourigan Lab, Washington, D.C., USA )

Complement-bound procoagulant platelets predict thrombosis in antiphospholipid...

Dr Keith McCrae - Cleveland Clinic, Cleveland, USA

Complement-bound procoagulant platelets predict thrombosis in antiphospholipid syndrome ( Dr Keith McCrae - Cleveland Clinic, Cleveland, USA )

More from ecancer